Neurology · Maitland, FL
Neurology studies in Maitland, FL
32 recruiting studies have a site in Maitland.
32 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Eli Lilly and Company
- Location
- Maitland, FL + 5 other US sites
- Eligibility basics
- Ages 45–85
- RecruitingHealthy volunteers
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment…
GAP Innovations, PBC
- Location
- Maitland, FL + 18 other US sites
- Eligibility basics
- Ages 60–90
- RecruitingPhase 3
[18F]PI-2620 Phase 3 Histopathological Study
Lantheus Biosciences Ltd.
- Location
- Maitland, FL + 16 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Maitland, FL + 24 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Maitland, FL + 24 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Merck Sharp & Dohme LLC
- Location
- Maitland, FL + 34 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Maitland, FL + 18 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Maitland, FL + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Maitland, FL + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Rapport Therapeutics Inc.
- Location
- Maitland, FL + 12 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Maitland, FL + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Alnylam Pharmaceuticals
- Location
- Maitland, FL + 3 other US sites
- Eligibility basics
- Ages 40–55
- RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Hoffmann-La Roche
- Location
- Maitland, FL + 11 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Maitland, FL + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Maitland, FL + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Maitland, FL + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Maitland, FL + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 1/Phase 2
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NKGen Biotech, Inc.
- Location
- Maitland, FL + 5 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Maitland, FL + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Genentech, Inc.
- Location
- Maitland, FL + 3 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Maitland, FL + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.
- Location
- Maitland, FL + 22 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Maitland, FL + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Voyager Therapeutics
- Location
- Maitland, FL
- Eligibility basics
- Ages 30–80
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.